What is Rua Bioscience?
Rua Bioscience, established in 2016 as a subsidiary of Hikurangi Enterprises Ltd, is a pioneering medicinal cannabis company based in the East Coast of New Zealand. The company distinguishes itself as a global innovator in plant breeding and genetics, focusing on the cultivation and processing of cannabinoid-based plants to develop clinically proven, safe, and effective medicines. With a mission to 'heal the people and heal the land,' Rua Bioscience is dedicated to advancing the global understanding of medicinal cannabis products and their therapeutic benefits. The company holds the distinction of being the first in New Zealand to receive a license for cultivating pharmaceutical-grade cannabis and the first to legally import high THC seeds, positioning it at the forefront of the industry.
How much funding has Rua Bioscience raised?
Rua Bioscience has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2025): $1.2M, investors not publicly disclosed
What's next for Rua Bioscience?
The recent major strategic investment signals a new phase of growth and development for Rua Bioscience. This capital infusion is expected to accelerate the company's research and development initiatives, enhance its cultivation and processing capabilities, and potentially expand its market reach. As a leader in plant genetics and pharmaceutical-grade cannabis, Rua Bioscience is well-positioned to capitalize on the growing global demand for high-quality medicinal cannabis products, further solidifying its commitment to innovation, sustainability, and healing.
See full Rua Bioscience company page
